SIM0237 with or without BCG for bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug, SIM0237, alone or with BCG, for people with a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC) that did not respond to BCG treatment. The goal is to see if it is safe and works against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC) that did not get better with BCG treatment.
- You have either carcinoma in situ (CIS) with or without other cancer changes, or high-grade Ta or T1 disease that did not respond to BCG.
- You are not a candidate for or have decided against having your bladder removed (radical cystectomy).
- You are 18 years or older and in reasonably good health with a life expectancy of at least 2 years.
- You agree to provide a tumor sample (old or new) for testing.
- You have not had certain prior treatments (like IL-15, IL-2, checkpoint inhibitors, or chemotherapy) within specific timeframes before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (FL115) given directly into the bladder, alone or with BCG, for people with a type of bladder cancer that has not responded to BCG therapy. It aims to find a better treatment option for those who cannot have or refuse bladder removal surgery.
This trial tests a new ablation therapy (a treatment that destroys tumors without surgery) in people with low-grade, non-invasive bladder cancer that comes back. It aims to see if this therapy can help avoid repeated surgeries.
This trial tests whether a new bladder cancer drug (SHR-1501) works alone or combined with BCG, and compares options with another drug (SHR-1316), in people with high-risk non–muscle-invasive bladder cancer. It may help reduce cancer coming back and improve control of the disease.
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
This trial tests a new form of intravesical (given directly into the bladder) treatment called rMBCG for people with non-muscle invasive bladder cancer who have not had BCG therapy before. It may be an option for those with certain types of early bladder cancer, including carcinoma in situ (CIS) or papillary tumors after removal surgery.
This trial studies whether bicalutamide can improve outcomes for people with non-muscle-invasive bladder cancer who are starting BCG through the bladder. It may help prevent cancer from coming back or progressing after BCG.
Hear when a new Non-Muscle-Invasive Bladder Cancer (NMIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.